EGFR Update: Improving Outcomes in EGFR-Mutated Non-Small-Cell Cancer episode artwork

EPISODE · Mar 29, 2022 · 26 MIN

EGFR Update: Improving Outcomes in EGFR-Mutated Non-Small-Cell Cancer

from Conversations in Lung Cancer Research · host Angeline Low, Rachel Roberts-Thomson, Venessa Chin

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Today Rachel Roberts-Thomson, Medical Oncologist from Queen Elizabeth Hospital in Adelaide, discusses Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer . Rachel is joined byVenessa Chin from St. Vincent’s Hospital in Sydney & Angeline Low who has her own personal experience with EGFR lung cancer .EGFR mutations are identified in approximately 15% of NSCLC patients. Efficacious, PBS-reimbursed first line treatments are available, but resistance to treatment and progression remains a concern. In this podcast, options for treatment post-progression are discussed, including accessible treatment and sequencing options and the role of patient preferences and clinical trials.In collaboration/partnership/supported with/by Roche.Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.  Note: SRS is Stereotactic radiosurgery Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube:  https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Episode metadata supplied by the publisher feed · Published Mar 29, 2022

Embed this episode

EGFR mutations are identified in approximately 15% of NSCLC patients. Efficacious, PBS-reimbursed first line treatments are available, but resistance to treatment and progression remains a concern. In this podcast, options for treatment post-progression are discussed, including accessible treatment and sequencing options and the role of patient preferences and clinical trials.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

EGFR Update: Improving Outcomes in EGFR-Mutated Non-Small-Cell Cancer

0:00 26:11

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Conversations in Lung Cancer Research?

This episode is 26 minutes long.

When was this Conversations in Lung Cancer Research episode published?

This episode was published on March 29, 2022.

Can I download this Conversations in Lung Cancer Research episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!